Department of Intensive Care, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.
Faculty of Medicine, Leiden University Medical Center, Leiden, The Netherlands.
Crit Care. 2020 Dec 14;24(1):696. doi: 10.1186/s13054-020-03400-9.
In the current SARS-CoV-2 pandemic, there has been worldwide debate on the use of corticosteroids in COVID-19. In the recent RECOVERY trial, evaluating the effect of dexamethasone, a reduced 28-day mortality in patients requiring oxygen therapy or mechanical ventilation was shown. Their results have led to considering amendments in guidelines or actually already recommending corticosteroids in COVID-19. However, the effectiveness and safety of corticosteroids still remain uncertain, and reliable data to further shed light on the benefit and harm are needed.
The aim of this systematic review and meta-analysis was to evaluate the effectiveness and safety of corticosteroids in COVID-19.
A systematic literature search of RCTS and observational studies on adult patients was performed across Medline/PubMed, Embase and Web of Science from December 1, 2019, until October 1, 2020, according to the PRISMA guidelines. Primary outcomes were short-term mortality and viral clearance (based on RT-PCR in respiratory specimens). Secondary outcomes were: need for mechanical ventilation, need for other oxygen therapy, length of hospital stay and secondary infections.
Forty-four studies were included, covering 20.197 patients. In twenty-two studies, the effect of corticosteroid use on mortality was quantified. The overall pooled estimate (observational studies and RCTs) showed a significant reduced mortality in the corticosteroid group (OR 0.72 (95%CI 0.57-0.87). Furthermore, viral clearance time ranged from 10 to 29 days in the corticosteroid group and from 8 to 24 days in the standard of care group. Fourteen studies reported a positive effect of corticosteroids on need for and duration of mechanical ventilation. A trend toward more infections and antibiotic use was present.
Our findings from both observational studies and RCTs confirm a beneficial effect of corticosteroids on short-term mortality and a reduction in need for mechanical ventilation. And although data in the studies were too sparse to draw any firm conclusions, there might be a signal of delayed viral clearance and an increase in secondary infections.
在当前的 SARS-CoV-2 大流行中,全世界一直在争论 COVID-19 中使用皮质类固醇的问题。在最近的 RECOVERY 试验中,评估了地塞米松的效果,结果表明需要吸氧或机械通气的患者 28 天死亡率降低。他们的结果导致考虑修改指南,或者实际上已经建议在 COVID-19 中使用皮质类固醇。然而,皮质类固醇的有效性和安全性仍然不确定,需要有可靠的数据进一步阐明其益处和危害。
本系统评价和荟萃分析的目的是评估 COVID-19 中皮质类固醇的有效性和安全性。
根据 PRISMA 指南,从 2019 年 12 月 1 日至 2020 年 10 月 1 日,在 Medline/PubMed、Embase 和 Web of Science 上对成年患者的随机对照试验和观察性研究进行了系统文献检索。主要结局是短期死亡率和病毒清除(基于呼吸道标本的 RT-PCR)。次要结局是:需要机械通气、需要其他氧疗、住院时间和继发感染。
共纳入 44 项研究,涵盖 20197 例患者。在 22 项研究中,定量了皮质类固醇使用对死亡率的影响。皮质类固醇组的总体汇总估计(观察性研究和 RCT)显示死亡率显著降低(OR 0.72(95%CI 0.57-0.87)。此外,皮质类固醇组的病毒清除时间为 10-29 天,标准治疗组为 8-24 天。14 项研究报告皮质类固醇对机械通气的需求和持续时间有积极影响。存在继发感染和抗生素使用增加的趋势。
我们从观察性研究和 RCT 中得出的发现证实,皮质类固醇对短期死亡率和减少机械通气需求有有益的影响。尽管研究中的数据过于稀疏,无法得出任何明确的结论,但可能存在病毒清除延迟和继发感染增加的信号。